Evaluation of immunotargeted gold nanoshells as rapid diagnostic imaging agents for HER2-overexpressing breast cancer cells: A time-based analysis

Lissett R. Bickford; Joseph Chang; Kun Fu; Jiantang Sun; Ying Hu; André Gobin; Tse Kuan Yu; Rebekah A. Drezek

doi:10.1007/s12030-008-9010-4

Evaluation of immunotargeted gold nanoshells as rapid diagnostic imaging agents for HER2-overexpressing breast cancer cells: A time-based analysis

Lissett R. Bickford, Joseph Chang, Kun Fu, Jiantang Sun, Ying Hu, André Gobin, Tse Kuan Yu, Rebekah A. Drezek

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Biomedical nanotechnology offers superior potential for diagnostic imaging of malignancy at the microscopic level. In addition to current research focused on dual-imaging and therapeutic applications in vivo, these novel particles may also prove useful for obtaining immediate diagnostic results in vitro at the patient bedside. However, translating the use of nanoparticles for cancer detection to point-of-care applications requires that conditions be optimized such that minimal time is needed for diagnostic results to become available. Thus far, no reports have been published on minimizing the time needed to achieve acceptable optical contrast of cancer cells incubated with nanoparticles. In this study, we demonstrate the use of gold nanoshells targeted to anti-HER2 antibodies that produce sufficient optical contrast with HER2-overexpressing SK-BR-3 breast cancer cells in only 5 min. This work validates the proof of concept that nanoshells targeted to extracellular biomarkers can be used to enhance cancer diagnostic imaging for use in point-of-care applications.

Original language	English
Pages (from-to)	1-8
Number of pages	8
Journal	Nanobiotechnology
Volume	4
Issue number	1-4
DOIs	https://doi.org/10.1007/s12030-008-9010-4
State	Published - Dec 2008
Externally published	Yes

Keywords

Cancer diagnosis
Nanoshells
Optical imaging
Point-of-care diagnostics

Access to Document

10.1007/s12030-008-9010-4

Cite this

@article{2da2d7f6935a41e49c4a76bd44773dcc,

title = "Evaluation of immunotargeted gold nanoshells as rapid diagnostic imaging agents for HER2-overexpressing breast cancer cells: A time-based analysis",

abstract = "Biomedical nanotechnology offers superior potential for diagnostic imaging of malignancy at the microscopic level. In addition to current research focused on dual-imaging and therapeutic applications in vivo, these novel particles may also prove useful for obtaining immediate diagnostic results in vitro at the patient bedside. However, translating the use of nanoparticles for cancer detection to point-of-care applications requires that conditions be optimized such that minimal time is needed for diagnostic results to become available. Thus far, no reports have been published on minimizing the time needed to achieve acceptable optical contrast of cancer cells incubated with nanoparticles. In this study, we demonstrate the use of gold nanoshells targeted to anti-HER2 antibodies that produce sufficient optical contrast with HER2-overexpressing SK-BR-3 breast cancer cells in only 5 min. This work validates the proof of concept that nanoshells targeted to extracellular biomarkers can be used to enhance cancer diagnostic imaging for use in point-of-care applications.",

keywords = "Cancer diagnosis, Nanoshells, Optical imaging, Point-of-care diagnostics",

author = "Bickford, {Lissett R.} and Joseph Chang and Kun Fu and Jiantang Sun and Ying Hu and Andr{\'e} Gobin and Yu, {Tse Kuan} and Drezek, {Rebekah A.}",

note = "Funding Information: Acknowledgments We thank Vengadesan Nammalvar and Adrien Wang for expert technical assistance on nanoshell fabrication. We also thank Nastassja Lewinski for SEM imaging and Christine Wogan for editing assistance. This work was supported by a Department of Defense Congressionally Directed Breast Cancer Research Program Era of Hope Scholar Award to Rebekah Drezek and Tse-Kuan Yu, the Center for Biological and Environmental Nanotechnology (EEC-0118007 and EEC-0647452), the Beckman Foundation, and the John and Ann Doerr Fund for Computational Biomedicine.",

year = "2008",

month = dec,

doi = "10.1007/s12030-008-9010-4",

language = "English",

volume = "4",

pages = "1--8",

journal = "Nanobiotechnology",

issn = "1551-1286",

publisher = "Humana Press",

number = "1-4",

}

TY - JOUR

T1 - Evaluation of immunotargeted gold nanoshells as rapid diagnostic imaging agents for HER2-overexpressing breast cancer cells

T2 - A time-based analysis

AU - Bickford, Lissett R.

AU - Chang, Joseph

AU - Fu, Kun

AU - Sun, Jiantang

AU - Hu, Ying

AU - Gobin, André

AU - Yu, Tse Kuan

AU - Drezek, Rebekah A.

N1 - Funding Information: Acknowledgments We thank Vengadesan Nammalvar and Adrien Wang for expert technical assistance on nanoshell fabrication. We also thank Nastassja Lewinski for SEM imaging and Christine Wogan for editing assistance. This work was supported by a Department of Defense Congressionally Directed Breast Cancer Research Program Era of Hope Scholar Award to Rebekah Drezek and Tse-Kuan Yu, the Center for Biological and Environmental Nanotechnology (EEC-0118007 and EEC-0647452), the Beckman Foundation, and the John and Ann Doerr Fund for Computational Biomedicine.

PY - 2008/12

Y1 - 2008/12

N2 - Biomedical nanotechnology offers superior potential for diagnostic imaging of malignancy at the microscopic level. In addition to current research focused on dual-imaging and therapeutic applications in vivo, these novel particles may also prove useful for obtaining immediate diagnostic results in vitro at the patient bedside. However, translating the use of nanoparticles for cancer detection to point-of-care applications requires that conditions be optimized such that minimal time is needed for diagnostic results to become available. Thus far, no reports have been published on minimizing the time needed to achieve acceptable optical contrast of cancer cells incubated with nanoparticles. In this study, we demonstrate the use of gold nanoshells targeted to anti-HER2 antibodies that produce sufficient optical contrast with HER2-overexpressing SK-BR-3 breast cancer cells in only 5 min. This work validates the proof of concept that nanoshells targeted to extracellular biomarkers can be used to enhance cancer diagnostic imaging for use in point-of-care applications.

AB - Biomedical nanotechnology offers superior potential for diagnostic imaging of malignancy at the microscopic level. In addition to current research focused on dual-imaging and therapeutic applications in vivo, these novel particles may also prove useful for obtaining immediate diagnostic results in vitro at the patient bedside. However, translating the use of nanoparticles for cancer detection to point-of-care applications requires that conditions be optimized such that minimal time is needed for diagnostic results to become available. Thus far, no reports have been published on minimizing the time needed to achieve acceptable optical contrast of cancer cells incubated with nanoparticles. In this study, we demonstrate the use of gold nanoshells targeted to anti-HER2 antibodies that produce sufficient optical contrast with HER2-overexpressing SK-BR-3 breast cancer cells in only 5 min. This work validates the proof of concept that nanoshells targeted to extracellular biomarkers can be used to enhance cancer diagnostic imaging for use in point-of-care applications.

KW - Cancer diagnosis

KW - Nanoshells

KW - Optical imaging

KW - Point-of-care diagnostics

UR - http://www.scopus.com/inward/record.url?scp=43049118985&partnerID=8YFLogxK

U2 - 10.1007/s12030-008-9010-4

DO - 10.1007/s12030-008-9010-4

M3 - Article

AN - SCOPUS:43049118985

SN - 1551-1286

VL - 4

SP - 1

EP - 8

JO - Nanobiotechnology

JF - Nanobiotechnology

IS - 1-4

ER -

Evaluation of immunotargeted gold nanoshells as rapid diagnostic imaging agents for HER2-overexpressing breast cancer cells: A time-based analysis

Abstract

Keywords

Access to Document

Fingerprint

Cite this